{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:10:48Z","timestamp":1777421448135,"version":"3.51.4"},"reference-count":23,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2016,12,5]],"date-time":"2016-12-05T00:00:00Z","timestamp":1480896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:p>Background: The introduction of anti\u2013tumor necrosis factor \u03b1 (anti-TNF\u03b1) drugs has improved the clinical outcomes in rheumatoid arthritis (RA) and ankylosing spondylitis (AS). However, these drugs may cause adverse effects that motivate a change in or discontinuation of the treatment. Objective: To evaluate the causes of discontinuation or changes in the dosage regimen in a cohort of patients with RA and AS treated with infliximab, adalimumab, etanercept, and golimumab under clinical practice conditions. Methods: This was a retrospective observational study that included patients with RA or AS treated with anti-TNF\u03b1 drugs between 2008 and 2013. Changes in the dosage regimen, reasons for treatment discontinuation, and adverse effects were recorded and analyzed. Time to discontinuation was estimated using Kaplan-Meier survival analysis. Results: A total of 123 patients with RA and 93 patients with AS were treated with anti-TNF\u03b1 therapy. During the study, 55.3% of RA patients and 41.7% of AS patients had stopped the treatment. The most frequent changes were modifications in the dosing, and the most frequent adverse effects were reactions after the infusion or injection (53.8% and 66.7% in RA and AS, respectively). Drug survival of etanercept in RA (67.9%) is greater than for adalimumab and infliximab, whereas drug survival of infliximab in AS (70.0%) is greater than for etanercept and adalimumab at 5 years, although there were no significant differences ( P = 0.098 in RA and 0.194 in AS). Conclusions: The main cause of discontinuation of anti-TNF\u03b1 is therapeutic failure in both diseases. Etanercept and infliximab have the best survival rates in RA and AS, respectively.<\/jats:p>","DOI":"10.1177\/1060028016682330","type":"journal-article","created":{"date-parts":[[2016,12,5]],"date-time":"2016-12-05T20:55:12Z","timestamp":1480971312000},"page":"388-393","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":15,"title":["Reasons for Discontinuation and Adverse Effects of TNF\u03b1 Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis"],"prefix":"10.1177","volume":"51","author":[{"given":"Mar\u00eda Henar","family":"Garc\u00eda-Lagunar","sequence":"first","affiliation":[{"name":"Department of Hospital Pharmacy, Santa Luc\u00eda General University Hospital (HGUSL), Cartagena, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Roc\u00edo","family":"Guti\u00e9rrez-C\u00edvicos","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Santa Luc\u00eda General University Hospital (HGUSL), Cartagena, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Sergia","family":"Garc\u00eda-Sim\u00f3n","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Santa Luc\u00eda General University Hospital (HGUSL), Cartagena, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Conesa-Zamora","sequence":"additional","affiliation":[{"name":"Department of Clinical Analysis, HGUSL, Cartagena, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Jimenez-Santos","sequence":"additional","affiliation":[{"name":"Department of Clinical Analysis, HGUSL, Cartagena, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Cano-Vivar","sequence":"additional","affiliation":[{"name":"Department of Cardiology, HGUSL, Cartagena, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s","family":"Garc\u00eda-M\u00e1rquez","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Santa Luc\u00eda General University Hospital (HGUSL), Cartagena, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Mu\u00f1oz-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Santa Luc\u00eda General University Hospital (HGUSL), Cartagena, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice Charlotte","family":"Viney","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Santa Luc\u00eda General University Hospital (HGUSL), Cartagena, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2016,12,5]]},"reference":[{"issue":"4","key":"bibr1-1060028016682330","first-page":"S10","volume":"27","author":"Lories RJ","year":"2009","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"bibr2-1060028016682330","first-page":"S15","volume":"27","author":"Appel H","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"bibr3-1060028016682330","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.1.88"},{"key":"bibr4-1060028016682330","first-page":"305","volume":"35","author":"Onen F","year":"2008","journal-title":"J Rheumatol"},{"key":"bibr5-1060028016682330","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.reuma.2012.02.010","volume":"8","author":"Ventura-Rios L","year":"2012","journal-title":"Reumatol Clin"},{"key":"bibr6-1060028016682330","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2009.10.006"},{"key":"bibr7-1060028016682330","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2006.06.011"},{"key":"bibr8-1060028016682330","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2006.042"},{"key":"bibr9-1060028016682330","first-page":"1","volume":"11","author":"McLeod C","year":"2006","journal-title":"Health Technol Assess"},{"key":"bibr10-1060028016682330","first-page":"2398","volume":"33","author":"Gartlehner G","year":"2006","journal-title":"J Rheumatol"},{"issue":"2","key":"bibr11-1060028016682330","first-page":"CD008794","author":"Singh JA","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr12-1060028016682330","doi-asserted-by":"publisher","DOI":"10.1590\/S1516-31802010000500013"},{"key":"bibr13-1060028016682330","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2012.04.007"},{"key":"bibr14-1060028016682330","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.04.010"},{"key":"bibr15-1060028016682330","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2013.04.012"},{"key":"bibr16-1060028016682330","first-page":"201","volume":"6","author":"Cantini F","year":"2012","journal-title":"Biologics"},{"key":"bibr17-1060028016682330","first-page":"1","volume":"7","author":"Cantini F","year":"2013","journal-title":"Biologics"},{"key":"bibr18-1060028016682330","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-015-2929-7"},{"key":"bibr19-1060028016682330","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2014.29.9.1205"},{"key":"bibr20-1060028016682330","first-page":"857","volume":"31","author":"Scire CA","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"bibr21-1060028016682330","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S47453"},{"key":"bibr22-1060028016682330","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22096"},{"key":"bibr23-1060028016682330","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204128"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028016682330","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028016682330","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028016682330","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:16:44Z","timestamp":1777375004000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028016682330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,5]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1177\/1060028016682330"],"URL":"https:\/\/doi.org\/10.1177\/1060028016682330","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,5]]}}}